Proposed framework: metabolic, inflammaging and senotherapy pillars for anti-aging
This abstract reviews anti-aging strategies and proposes that metabolic modulation, inflammaging control and senotherapy form three interconnected pillars; many approaches showed promise mainly in preclinical models, with some in clinical trials. [1]
Automatic summary · not editorially reviewed
The key findings
The abstract proposes metabolic modulation, inflammaging control and senotherapy as three interconnected pillars of anti-aging strategies. [1]
Listed strategies include exercise, calorie restriction, calorie restriction mimetics, senotherapy, parabiosis, stem cell-based therapies and epigenetic rejuvenation. [1]
Some strategies showed promise in preclinical models, and some demonstrated efficacy in clinical trials. [1]
The source at a glance
- Study type / format
- Review abstract
- Population / context
- Aging and age-related diseases in the general population, plus preclinical models and some clinical trial participants.
- Summary based on
- Study abstract
- Original publication
- September 1, 2026
Review context: rising aging burden and proposed pillars
The abstract states that aging and age-related diseases have become markedly more common in recent decades because life expectancy has risen and the aging population has grown, creating medical and social burdens. It reviews leading anti-aging interventions and proposes that metabolic modulation, inflammaging control and senotherapy are three interconnected pillars of contemporary anti-aging strategies.
Supporting source [1]
Strategies listed and mechanisms described in the abstract
The listed strategies include metabolic modulation such as physical exercise, calorie restriction and calorie restriction mimetics, targeting inflammaging, senotherapy, parabiosis, stem cell-based therapies and epigenetic rejuvenation. The described mechanisms include enhancing autophagy, clearing senescent cells and supporting mitochondrial function to reduce chronic inflammation.
Supporting source [1]
Preclinical promise versus limited clinical evidence
According to the abstract, these strategies have shown promise in slowing aging and extending lifespan in preclinical models, and some have shown efficacy in clinical trials. The abstract does not report which interventions reached trials, trial sizes, outcomes or effect sizes, so the clinical extent remains unclear.
Supporting source [1]
How to interpret this
This is an abstract only; the full text was not reviewed. It does not specify which interventions reached clinical trials, trial designs, sample sizes, outcomes or effect sizes, and preclinical lifespan findings are not human benefits.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Li F, Wang Y, Wang G, Chen J, Huang S. · europepmc.org · September 1, 2026